Octagon Research Solutions announced its two additions to its Quantum Regulatory Information Management platform. Content Manager and Document Publisher join Submission Manager as the next applications built on Octagon’s Quantum Platform. This new platform provides industry with a single, consolidated system to provide highly scalable, and top tier capabilities to life science companies.
The Quantum Content Manager Business Application provides process controls across the document lifecycle and offers a secure and collaborative environment for content creation, review, and finalization.
The Quantum Document Publisher Business Application provides PDF manipulation functionality supporting:
Combined with Octagon’s existing Submission Manager application, organizations have the capability to develop and publish content from a single, flexible, and pre-configured system.
“We are very pleased to be able to preview these two business modules that leverage the strong process management capabilities of the Quantum platform,” said James C. Walker, chairman and CEO, Octagon Research Solutions, Inc. “Content Manager and Document Publisher address the challenges of managing the document lifecycle while improving the quality, consistency and value of the final content deliverables.”
The two new business applications are integral components of Octagon’s cloud strategy. Though the Quantum platform and business modules are available in a traditional on-premise installation, the release of these new modules enables Octagon to provide an end-to-end, cloud-based solution that joins document and submissions lifecycles in a hosted environment.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.